Ken Griffin Precipio, Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.6 - $1.0 $14,707 - $24,512	-24,512 Reduced 43.84%	31,406 $20,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $17.4 $27,959 - $972,973	55,918 New	55,918 $30,000
Q1 2022 May 16, 2022	SELL	$1.19 - $1.71 $19,245 - $27,655	-16,173 Reduced 54.91%	13,282 $18,000
Q2 2021 Aug 16, 2021	BUY	$1.8 - $5.25 $53,019 - $154,638	29,455 New	29,455 $106,000
Q1 2021 May 17, 2021	SELL	$2.1 - $3.89 $31,552 - $58,447	-15,025 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.94 - $2.64 $29,148 - $39,666	15,025 New	15,025 $31,000

340

Ticker PRPO
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 22,736,500
Market Cap $143M
Description
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust geneti...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.